A one-year time frame for voice prosthesis management. What should the physician expect? Is it an overrated job?
Management of late complications represents the main reason for reluctance in using voice prosthesis rehabilitation. The aim of this paper is to report our experience by describing the one-year management of a large cohort of patients in order to clarify how demanding management is in terms of burden on clinicians. Between June 2017 and June 2018, each access made at the Otolaryngology Clinic of our Institute for issues related to prosthesis by 70 laryngectomised patients rehabilitated by voice prosthesis was registered in a specic database. A review of the data provided information on the incidence, management and outcomes of adverse events encountered during the selected time frame. In addition, a T test was used to evaluate the differences between irradiated and non-irradiated patients and between primary and secondary tracheo-oesophageal-puncture. Leakage through the prosthesis was the most common cause for access (51.86%). The median number of accesses per patient per year was 3.47. The speech therapist autonomously managed 18.1% of accesses. The median number of accesses per patient per year needing a physician was 2.84. The median lifetime of the prosthesis was 4.85 months. Radiotherapy or modality (primary or secondary) of the puncture did not inuence the number of accesses per year or the prosthesis lifetime. This retrospective analysis of results highlighted the most frequent issues and the most effective measures to deal with them, which allowed us to dene a systematic algorithm to standardise and ease long-term outpatient management.
Over the last 30 years, trachea-oesophageal speech (TES) has become the gold standard for rehabilitation following total laryngectomy 1 thanks to a more natural sounding voice, superior voice quality, shorter rehabilitation time 2,3 and a higher success rate (ranging from 60 to 90%) 4 compared with other rehabilitation methods.
Generally speaking, it is recognised that four main reasons hinder the widespread use of TES: surgical complications (early complications), long-term voice prosthesis/fistula troubles (late complications), cost of devices and burden on physicians.
Early complications are in most cases “minor” (e.g. trauma to the lips/teeth, superficial mucosal lacerations), both in primary and secondary settings 5. Major complications (e.g. oesophageal perforation) are quite rare and always related to difficult secondary puncture 6-10. Diagnosis and management of early minor and major complications is beyond the scope of this paper, but the general worldwide orientation is a preference, as much as possible, for primary punctures to reduce the risk of major, life-threatening complications.
Our focus is on late complications, which could be considered unavoidable consequences of the fistula and/or of the presence of a foreign body (i.e. voice prosthesis). The management of these issues is considered time demanding, often causes anxiety in non-experienced non-specifically trained specialists and, in the real world, it represents the main obstacle for many physicians to voice prosthesis rehabilitation. Voice prosthesis patients are, in fact, notoriously characterised by much more frequent visits to healthcare professionals than oesophageal speakers. Some late sequelae are easy to manage, whereas others may challenge even the most experienced clinician 11.
The lifetime of voice prostheses is one of the limitations of TES, representing the need for ongoing replacement of the valve 12. The main cause (80%) for replacement of an indwelling device is internal leakage (intravalvular leakage) due to the contamination by a biofilm of bacteria and yeasts that renders the valve incompetent 13,14.
Leakage around the prosthesis is often due to the gradual thinning of the tracheo-oesophageal-puncture site (TEP), and consequent shortening of the prosthesis is a natural course of events, representing about 10% of all voice prosthesis substitutions 17-21.
The aim of this paper is to analyse a 1-year window of troubleshooting in a multidisciplinary setting for a large cohort of voice prosthesis rehabilitated patients, to quantify how demanding management is and to propose an algorithm that is useful to minimise the time and burden for dedicated clinicians.
Materials and methods
Between June 2017 and June 2018, 70 voice prosthesis patients made 243 accesses at the Otolaryngology Clinic and Phoniatric Unit of our Institute for issues related to their prosthesis. In our centre, there is a dedicated team for management of voice prosthesis patients consisting of 2 ENT surgeons and 3 speech therapists. Each team member has specific training and is able to perform patient visits to evaluate the voice prosthesis, fistula and peristomal tissues.
The median age was 65.12 ± 6.53 years (range 54-80 years). All patients had undergone total laryngectomy with bilateral neck dissection and TEP for voice restoration. All patients included in the study had undergone primary closure of the pharynx, except for three free flap non-tubed reconstructions (2-anterolateral thigh and 1 forearm) in the salvage setting after concomitant radio-chemotherapy.
Forty-six patients had been subjected to primary (n = 12/26.08%) or adjuvant (n = 34 /73.91%) radiotherapy.
In 28 of 70 patients (40%), a secondary TEP was chosen.
The interval between total laryngectomy and prosthesis implantation varied from 2 to 108 months (25.38 ± 27.55).
All patients were primarily trained by the speech therapist in the use and maintenance of the fistula and prosthesis. Speech therapy rehabilitation began on the 10th-12th post-operative day for patients undergoing primary TEP, after the removal of the nasogastric tube. For patients with secondary TEP, rehabilitation started 24 hours after the operation. Speech therapy provided coordination exercises, which included breath and digital stoma occlusion, production of vocalisations, bi-syllabic and polysyllabic words, automatic series and sentences with increasing length. Subsequently, patients worked on the production of exclamatory or interrogative sentences, reading short passages and conversations. Finally, specific training was carried out to improve the control of rhythm and modulation and intensity variations. Speech therapy had variable timing based on each individual case (from 10 to 20 sessions, with a median of 12 sessions). No patient ever used the Electrolarynx.
Since June 1st, 2017, each access was registered in a specific database. A review of these medical records provided information on the incidence, management and outcomes of adverse events encountered during the selected time frame (1 June 2017-1 June 2018). The data were managed as hand-entry during routine practice and the records were then interrogated as a chart/case review. The appointed person for managing this data was speech therapist.
Data used were retrospectively gathered from existing data sources. Approval from the Local Ethics Committee was obtained.
Statistical analysis was performed using JMP software, release 7.0.1, from the SAS Institute. The α level was fixed at 0.05.
Paired T test was used to evaluate the differences between patients subjected to radiotherapy vs non-irradiated patients and between primary and secondary TEP.
Leakage through the prosthesis occurred in 125 accesses (51.86% of overall accesses). In 15 of 125 internal leakages, the speech therapist resolved the issue. In 110 of 125 accesses, the physician resolved the issue. The solutions adopted are summarised in Table I.
Leakage around the prosthesis was noted in 60 accesses made by 29 of 70 patients (24.69% of overall accesses, 41.42% of patients). On most occasions, it was due to an over-long prosthesis moving back to create a piston-effect. Before coming to medical examination, 14 cases were resolved by the speech therapist. In 46 of 60 accesses, the leakage around the prosthesis was resolved by a physician. The solutions adopted are summarised in Table II.
Some patients developed aphonia or dysphonia, immediate or delayed, showing excessive vocal effort (28 accesses, 11.52%). The first step in the management of this problem was speech therapist evaluation, who resolved it in 10 of 28 cases. In 14 of 28 cases, the dysphonia/aphonia was resolved by a physician. Three of 14 patients were treated with chemical denervation with botulinum toxin. In 4 accesses (3 of which by the same patient), no attempt was successful in resolving the excessive vocal effort. The solutions used are summarised in Table III.
A growing circumferential granuloma at the tracheal wall of the puncture was observed in 16 accesses (6.58%). In three cases, the replacement was avoided by the speech therapist. In 13 of 16 accesses, the physician resolved the issue. The solutions used are summarised in Table IV.
On 8 occasions patients presented to our clinic because > 8 months has passed since the last substitution (3.29%). They had no leakage or any other complication. They underwent a check-up by a speech therapist to assess the condition of the prosthesis. 2 of these 8 patients (25%) did not require a replacement. 6 patients underwent replacement because of the poor condition of the prosthesis (75%), in particular 1 replacement with a longer one (16.6%), 4 with an analogous one (66.6%) and 1 with a shorter one (16.6%).
Two patients who ingested the voice prosthesis (0.82%) were managed by reinsertion of the prosthesis in the operating room by secondary technique.
In two patients, granuloma formation caused voice prosthesis spontaneous extrusion (0.82%). In one case, the prosthesis was immediately reinserted using the retrograde technique. For the remaining patient, it was necessary to replace the prothesis in the operating theatre.
Finally, we recorded a dislocated prosthesis (0.36%) that was resolved by replacement with an analogous one and an oesophageal pocket (0.36%) caused by overgrowth of mucosa, which was resolved by replacing the voice prosthesis with a longer one via retrograde technique.
In our series, the median number of accesses per patient per year was 3.47. The total number of exclusive speech therapist treatments was 44 of 243 (18.1%), and in these cases the surgeon or phoniatrician did not see the patient. In the case of exclusive management by a speech therapist, the prostheses had an average lifetime of 6.07 ± 6.49 weeks (range 1-27.57 weeks).
Consequently, the median number of accesses per patient per year needing physician treatment was 2.84. The median prosthesis lifetime was 4.85 months.
Student’s T test showed that radiotherapy did not influence the number of accesses per year. No statistically significant difference between the irradiated group and non-irradiated group of patients was found (respectively 3.63 ± 2.98 vs 3.54 ± 2.57, p > 0.05). In addition, comparison of the prosthesis lifetime between irradiated and non-irradiated patients did not show any significant difference (respectively 4.27 vs 4.88 months, p > 0.05). The same result was found comparing the median number of accesses of patients undergoing primary puncture with patients undergoing secondary puncture. The difference was not significant (respectively, 3.13 and 4.13, p > 0.05). We did not analyse the differences between primary pharynx closure vs. free flap reconstruction because the latter was performed on only 3 of the 70 patients in our cohort.
It is well demonstrated that voice prosthesis currently represents the gold standard in rehabilitation of laryngectomised patients 24,25. Nevertheless, reluctance with regards to the widespread use of these devices is still present among surgeons, phoniatricians and speech therapists.
The main reason for this reticence arises from the burdensome management of late sequelae together with the cost of devices. To address the first issue, we analysed a 1-year time frame of management in a large cohort of voice prosthesis rehabilitated patients and, as a result, we developed a trouble-shooting algorithm with a technical flow chart to achieve quick and correct identification and adequate treatment of complications (Fig. 1).
Our results show that it is important to verify the status of the prosthetic device at each outpatient evaluation, and, if there are any problems, to establish their exact nature, determine the indication for replacement (leakage through or around, infection of the fistula tract, etc.) and determine the required length of the new prosthesis.
Specifically, when an intravalvular leakage (the most frequent issue) occurred, an analogous prosthesis is the solution in most cases (70.9 % of cases in our series), because in this specific case we are dealing with a prosthesis-related problem. However, our experience suggested that we should never automatically replace the existing device with another of the same size. In fact, even if the leakage is intravalvular, a different length of prosthesis is sometimes needed. In most of these cases (in our series 22.72%), a shorter prosthesis is needed because of shrinkage of the tracheoesophageal wall, otherwise a perivalvular leakage or speaking effort because of the piston effect on the posterior oesophageal wall may be experienced. Rarely (2.72% in our series), a longer prosthesis can be indicated because of the synchronous presence of hypertrophic/granulation tissue.
When intravalvular leakage occurs too frequently and patients experience a device lifetime of 4 to 8 weeks, or even less 26, it is necessary to adopt a specialised voice prosthesis equipped with tiny magnets to effectively close the valve, and Candida-resistant material to decrease fungal colonisation 27 (Provox ActiValve ATOS® Atos Medical AB, Horby, Sweden). This solution was used in our series in only 2.72% of cases.
According to the literature 28 and in the present series, the second most common reason for voice prosthesis replacement is peripheral leakage. In these cases, our approach considers the following sequence: downsizing (insertion of a shorter prosthesis); replacement with an analogous prosthesis (same size) via overshooting if leakage is due to dislocation of the oesophageal flange into the wall; extra-flange prosthesis (in our experience the Xtra-seal prosthesis-ATOS® Atos Medical AB, Horby, Sweden); ring application; tissue augmentation (to increase the TEP tract with injectable silicone or autologous fat); surgical closure of the fistula (when required). We intentionally excluded purse string sutures on the fistula tract because in our experience it did not resolve a single case of periprosthetic leakage. In most cases, in fact, it depends on party wall resorption, and therefore the solution is not to shrink it but to augment it. Massive TEP enlargement occurs very seldom, but this adverse event can be a considerable burden on patients and head and neck teams. Some clinicians suggest temporary prosthesis removal allowing the TEP to shrink, but this requires a feeding tube and a cuffed cannula and this is not very appealing to patients. Some authors 29 suggest that a massive TEP enlargement is the result of a prolonged use of a voice prosthesis that is too long because of its pistoning effect. Precise analysis of this aspect and a proper solution (shorter prosthesis) is the key indication to avoid this troublesome complication.
In cases of effort in voicing due to a hypertonicity or spasm of the pharyngo-oesophageal musculature, confirmed in the diagnostic work-up by a lidocaine test, the solution was Botulinum toxin injection. We have never used neurectomy of plexus pharingeus and secondary myotomy. In two of 5 patients who underwent botulinum toxin injections, we temporarily resolved the problem and an additional injection was programmed.
Interestingly, in our series, patients who had undergone radiotherapy (preoperative or post-operative) did not show any significant differences from non-irradiated patients in terms of number of accesses to the outpatient clinic or prosthesis lifetime. These data confirm what has already been demonstrated in the literature regarding equivalent late complication rates in the two subgroups of patients 30-32.
Similarly, no significant differences in the incidence of late complications or management were detected between patients with primary puncture and secondary puncture, according to the literature. In fact, only an intraoperative or early post-operative different rate of complications was demonstrated between the two techniques 7-9. In particular, major surgery-related complications are described only in secondary punctures. This explains our recent orientation towards primary puncture, reserving secondary punctures for patients from other centres who have failed oesophageal vocal rehabilitation or who are not satisfied with their vocal quality.
Finally, our results showed the central role of the speech therapist in the management of TES patients. In fact, 18.1% of accesses were resolved exclusively by speech therapists, reducing the number of accesses needing physician treatment/advice, and leading to a significant reduction in costs and time.
Our study highlights the importance of a systematic approach in the management of late complications in voice prosthesis rehabilitated patients. A flow chart with a trouble-shooting algorithm may guide clinicians in the precise detection and adequate treatment.
The management of late complications is one of the main reasons for the reluctance in using voice prosthesis rehabilitation. Problems occur, despite surgeons’ best efforts, as an unavoidable consequence of the presence of a foreign body, represented by the prosthesis. Strict adherence to a tailored trouble-shooting algorithm may offer an easy solution to the most common complications. In a multidisciplinary setting, an initial visit by a speech therapist is useful to render the burden of voice prosthesis management reasonably acceptable for the surgeon, especially in a tertiary referral centre where the high number of patients may become a highly demanding task.
Figures and tables
|Leakages through the prosthesis solved by speech therapist||Deep cleaning of the prosthesis with brush, flush and aspirator||15/125 (12%)|
|Prosthesis reinsertion in leakages through the prosthesis||110/125 (88%)|
|TEP replaced with analogous one||78/110 (70.90%)|
|TEP replaced with shorter one||25/110 (22.72%)|
|TEP replaced with longer one||3/110 (2.72%)|
|TEP replaced with specialised one equipped with tiny magnets (ProvoxActiValve ATOS ® )||3/110 (2.72%)|
|TEP replaced with longer one via retrograde technique||1/110 (0.90%)|
|Leakages solved by speech therapist||Deep cleaning of the prosthesis or its relocation in situ||14/60 (23.33%)|
|Prosthesis reinsertion in leakages around the prosthesis||39/60 (65%)|
|TEP replaced with a shorter one||22/39 (56.41%)|
|TEP replaced with analogous one via overshooting replacement||12/39 (30.76%)|
|TEP replaced with specialised one with double oesophageal flange (ProvoxXtra-seal ATOS ® )||3/39 (7.69%)|
|TEP replaced with a longer one||2/39 (5.12%)|
|Leakages solved with a silicon ring||4/60 (6.66%)|
|Leakages solved with injectable silicone||3/60 (5%)|
|Aphonia/dysphonia solved by speech therapist||Relaxation exercises for the cervical area, manipulation, facilitating manoeuvres, change of posture, relaxed phonation with pulmonary support, decrease of volume and soft voice attack||10/28 (35.71%)|
|Prosthesis reinsertion in aphonia/dysphonia||11/28 (39.28%)|
|TEP replaced with analogous one via an overshooting replacement||6/11 (54.54%)|
|TEP replaced with a longer one||3/11 (27.27%)|
|TEP replaced with a shorter one||1/11 (9.09%)|
|TEP replaced with a longer one via retrograde technique||1/11 (9.09%)|
|Aphonia/dysphonia resolved with botox injection||60 units, 15 units in 4 different points, under electromyographic monitoring||3/28 (10.71%)|
|Issue solved by speech therapist||Relocation in situ of the prosthesis||3/16 (18.75%)|
|Prosthesis reinsertion in granuloma||13/16 (81.25%)|
|TEP replaced with analogous one via overshooting||6/13 (46.15%)|
|TEP replaced with a longer one||6/13 (46.15%)|
|TEP replaced with a longer one via retrograde technique||1/13 (7.69%)|